Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Entera Bio Ltd. (ENTX)

DiaMedica Therapeutics, Inc. and Entera Bio Ltd. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Entera Bio Ltd. are of similar size ($462.4M and $449.2M). Across the 8 metrics below, DiaMedica Therapeutics, Inc. leads on 4 and Entera Bio Ltd. on 4.

Valuation

Metric DMAC ENTX Biotechnology median
P/E n/m n/m 8.56
P/S n/m 599.53 10.17
P/B 11.58 18.40 2.34
Price to free cash flow n/m n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales n/m 534.34 9.64
Earnings yield (8.74%) (13.21%) (29.41%)
Free cash flow yield (7.10%) (8.22%) (23.50%)

Profitability

Metric DMAC ENTX Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (114.62%) (138.92%) (56.66%)
Return on assets (98.18%) (87.02%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC ENTX Biotechnology median
Revenue growth (TTM) — 66.42% 5.64%
EPS growth (last fiscal year) (16.67%) 0.00% 30.08%
Revenue growth, 5-year CAGR — (29.19%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC ENTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 8.98 4.72
Net debt to EBITDA 1.70 1.29 0.96

Dividend

Metric DMAC ENTX Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric DMAC ENTX Biotechnology median
Market cap 449.20m 462.40m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack